DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
AG-120 is an investigational drug.
There have been 19 clinical trials for AG-120. The most recent clinical trial was a Phase 1 trial, which was initiated on June 1st 2017.
The most common disease conditions in clinical trials are Leukemia, Myeloid, Acute, Leukemia, Myeloid, and Myelodysplastic Syndromes. The leading clinical trial sponsors are Agios Pharmaceuticals, Inc., National Cancer Institute (NCI), and Celgene Corporation.
There are five US patents protecting this investigational drug and ninety-one international patents.
Recent Clinical Trials for AG-120
|Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation||National Cancer Institute (NCI)||Phase 1|
|Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation||City of Hope Medical Center||Phase 1|
|CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome||National Cancer Institute (NCI)||Phase 2|
Top disease conditions for AG-120
Top clinical trial sponsors for AG-120
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|AG-120||Start Trial||Pharmaceutical compositions of therapeutically active compounds||Agios Pharmaceuticals, Inc. (Cambridge, MA)||Start Trial|
|AG-120||Start Trial||Methods and compositions for cell-proliferation-related disorders||Agios Pharmaceuticals, Inc. (Cambridge, MA)||Start Trial|
|AG-120||Start Trial||Therapeutically active compositions and their methods of use||Agios Pharmaceuticals, Inc. (Cambridge, MA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|